GlassScriptPhysician profile
Franklin K Bufford
NPI 1083706758
$7,103.25
in general payments reported to CMS, 2019-2025
50 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $927 · 2021: $1,177 · 2022: $972 · 2023: $1,034 · 2024: $1,354 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,532.23 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,081.49 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $458.39 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $405.43 | 2019-2020 | |
| Abbott Laboratories | $346.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $290.13 | 2019-2025 | |
| Corium, LLC | $279.04 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $252.80 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $224.68 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $208.62 | 2019-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $167.28 | 2021 | |
| Supernus Pharmaceuticals, INC. | $138.51 | 2021-2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.01 | 2019-2024 | Xifaxan, Trulance |
| Antares Pharma, INC. | $111.34 | 2020-2022 | |
| Amgen INC. | $107.06 | 2019-2025 | Otezla, Repatha |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Bufford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.